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Summary Using vanadyl sulphate, sodium orthovanadate or bis(maltolato)oxovanadium (BMOV), Cruz TF, Morgan A, Min W (1995, MolCell
Biochem 153: 161-166) have recently demonstrated the antineoplastic effects of vanadium in mice. In this study, the antineoplastic effects of
BMOV against human tumour cell lines was confirmed, and this effect was shown to depend on the prolonged exposure of the cells to the
drug. We have investigated a polymeric drug delivery system for the sustained delivery of BMOV as an antineoplastic agent in mice. The
objective was to design and evaluate an injectable polymer-BMOV paste that would act as a drug implant for the slow but sustained release
of BMOV in the mice. In vitro studies showed that the biodegradable polymer poly (Ghlr epsilon E-caprolactone) (PCL) released BMOV in a
sustained manner with rates of drug release increasing with increased loading of the drug in the polymer. In vivo studies showed that
PCL-BMOV paste implants produced a concentration-dependent inhibition of MDAY-D2 tumour growth via systemic drug delivery. Further in
vivo studies showed that 5% BMOV-loaded PCL (containing 20% methoxypolyethylene glycol) was effective in preventing tumour regrowth of
resected RIF tumour masses in mice when the PCL-BMOV paste was applied to the resected site for localized drug delivery. The results
confirm the potential of vanadium as an antineoplastic agent and show that the injectable PCL-BMOV formulation releases a
chemotheraputic dose of vanadium for the systemic treatment of whole tumours as well as the localized treatment of resected RIF tumours.
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Vanadium is a potent in vitro inhibitor ofvarious enzymes, such as
Na+, K+-ATPase, Ca2+ ATPase and various protein tyrosine phos-
phatases (Swarup et al, 1982; Jandhyala et al, 1983). Although
normally present in plasma at submicromolar levels, increased
concentrations ofvanadium in plasma influence insulin sensitivity,
vascular resistance and renal function (Jandhyala et al, 1983;
McNeill et al, 1992). Mitogenic effects of vanadium have been
reported previously (Carpenter, 1981 Kingsnorth et al, 1986;
Montesano et al, 1988; Stem et al, 1993), and there is some
evidence indicating a tumour-promoting potential of vanadium
(Sabbioni et al, 1993; Stem et al, 1993; Chakraborty et al, 1995).
In contrast to this, vanadium has been reported to have anti-
carcinogenic effects (Thompson et al, 1984; Bishayee et al, 1995)
and to inhibit tumour cell growth (Kopf-Maier et al, 1981; Sardar
et al, 1993).
The antineoplastic effects of vanadium have recently been
confirmed both in vitro and in vivo (Cruz et al, 1995.). More than
85% inhibition of tumour growth was achieved following daily
subcutaneous injections of 500 [tg of orthovanadate into mice
bearing the MDAY-D2 tumour grown in mice. Further studies
showed that the vanadyl sulphate, orthovanadate and the organic
vanadium complex, bis(maltolato)oxovanadium (BMOV) were
all effective antineoplastic agents (personal communication, TF
Cruz). It was noted that the mice showed some stress immediately
Received 19August 1996
Revised 7 October 1996
Accepted 16 October 1996
Correspondence to: HM Burt
after injection ofthe large doses ofvanadium indicating that some
of the toxicity is caused by the high initial plasma concentrations
following vanadium administration. Continuous administration of
vanadium compounds at lower plasma concentrations may prevent
the toxicity associated with a bolus administration.
We have developed a slow-release polymeric surgical paste
drug delivery system for the anti-cancer agent, taxol, for potential
application at tumour resection sites to prevent local recurrence of
disease (Winternitz, 1996). The poly (E-caprolactone) (PCL)-
based paste is applied to a tissue site in the molten state (about
55°C) where it solidifies rapidly to a hard waxy implant at 37°C.
In this study, we have investigated the suitability of the PCL
paste as a delivery vehicle for the organic vanadate complex,
BMOV. BMOV is a substantially more hydrophobic and less
water-soluble form of vanadium (Yuen et al, 1993a) and is there-
fore preferable for the development of a controlled release drug
delivery system.
The objectives of this work were to develop and characterize a
PCL-BMOV formulation and determine its effectiveness both in
the systemic treatment of MDAY-D2 tumour-bearing mice and in
the local treatment ofpartially resected tumours in mice.
MATERIALS AND METHODS
Polymer formulations
Poly(r-caprolactone) (molecularweight 20 000) (BPI Birmingham,
AL, USA) and BMOV (a generous gift from Dr J McNeill) were
weighed directly into a glass beaker in the appropriate proportions.
In some formulations, methoxypolyethylene glycol (MEPEG)
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(molecular weight 350) (Union Carbide, Danbury, CT, USA)
was also added to the PCL and BMOV. The beaker and contents
were warmed to 55°C with gentle stirring for 5 min until the
BMOV was thoroughly dispersed in the molten polymer. The
molten mix was then drawn into a prewarmed syringe and stored
at 4°C until use.
Drug-release studies
To tubes containing 15 ml of 10 mm phosphate-buffered saline
(PBS, pH 7.4) and 100 [tg ml-' bovine serum albumin (Fraction
5;Boehringer Mannheim, Germany) were added 150 mg disc-
shaped slabs of PCL-BMOV paste. The tubes were sealed and
tumbled end over end at 30 r.p.m. at 37°C. At appropriate times,
the PCL-BMOV slab was allowed to settle undergravity for 5 min
and all the supernatant was removed. The BMOV concentration
was determined in the supematants by measuring the absorbance at
256 nm (A256) and 276 nm (A276). The supernatant was replaced
with 15 ml of fresh PBS and the tubes were retumbled. A linear
calibration curve of BMOV concentration vs A256 or A276 was
obtained using BMOV standards in the 0-25 jig ml-' range. The
absorbance values at 256 nm or 276 nm of these standards were
shown to be unaffected by storage in sealed tubes at 37°C for 2-3
days (the same conditions used for drug-release studies). At the
end of the drug-release experiments, samples of the PCL-BMOV
matrix were assayed for residual drug content by dissolution of a
known dried weight of the matrix in 0.5 ml of dichloromethane
(DCM) (Fisher). To this solution was added 50 ml of warm water
(50°C) with mixing to evaporate the DCM, leaving the BMOV in
water for spectrophotometric analysis (A256).
Scanning electron microscopy (SEM)
Samples of the PCL-BMOV matrix that had been used in the 2-
month drug-release experiments were examined using SEM.
These samples were compared with freshly prepared control
samples. Polymer samples were coated (60:40 gold:palladium)
(Hummer Instruments, Technics, USA) and examined using a
Hitachi (model F-2300) scanning electron microscope with an
IBM data collection system.
Human tumour cell lines
The HT-29 colon, MCF-7 breast and SKMES1 non-small-cell lung
human tumour cell lines were obtained from the American Type
Culture Collection. The HT-29 colon cell line was cultured in
RPMI-1640 medium with 10% heat-inactivated fetal bovine serum
(HIFBS); the MCF-7 breast cell line in Iscove's modified Eagle
medium with 5% HIFBS plus 10-9 M insulin; and the SKMES1 lung
cell line in Eagle minimal essential medium with 10% non-heat-
inactivated FBS. The use of these cell lines to determine the anti-
neoplastic activity of various agents has been described previously
(Scheithauer etal, 1986; Arteaga et al, 1987; Hanauske, 1989).
Normal human marrow cells
Normal human bone marrow (histologically negative for tumour
cells) was obtained from patients who were to have bone marrow
transplants for their solid tumours but died before the marrow was
used. After centrifugation, the buffy coat was removed and cells
were treated with lysis buffer and washed twice with and then
resuspended in RPMI-1640 medium with 20% HIFBS. The cells
were drawn through a 25G needle and counted.
Radiometric (Bactec) system
The Bactec system (Johnston Laboratories, Towson, MD, USA) is
based on a clinical instrument, which was developed to detect
bacteria in blood cultures. The instrument has been used to screen
for new antineoplastic agents (Von Hoff et al, 1985). This radio-
metric system is a rapid, semi-automated system that uses the inhi-
bition of the conversion of ['4C]glucose to '4CO2 as an index of
cytotoxicity. The Bactec instrument automatically flushes out the
14CO2 into an ion chamber where the signal of the radiolabelled
CO2 is changed into a proportional electrical signal or growth
index value on a scale of 1 to 1000. For the continuous exposure,
the tumour cells or normal marrow cells were added to 2 ml ofthe
appropriate growth medium containing 2 [iCi of ['4C]glucose plus
BMOV at final concentrations of0.01,0.1,1, 10,25 and 50 uM and
injected into 20-ml rubber-stoppered serum vials, which contained
a mixture of5% carbon dioxide and air, and incubated at 37°C for
24 days. For 1-h exposure, cells and BMOV at the same final
concentrations used in the continuous exposure vials were incu-
bated in 15-ml polypropylene conicals in a 370C water bath for 1
h. The cells were then centrifuged and washed in medium, then
resuspended in 2 ml ofthe appropriate growth medium containing
2 [lCi of [14C]glucose and injected into 20-ml rubber-stoppered
serum vials, which contained a mixture of5% carbon dioxide and
air, and incubated at 370C for 24 days. At days 6,9 and 12
for tumour cell lines and days 6,15 and 24 for marrow cells, the
vials were removed and inserted into the Bactec instrument for
determination of the amount of '4CO2 produced by the cells upon
metabolizing the [14C]glucose. The growth index values of
BMOV-treated cells were compared with the growth index values
of non-treated cells and the percentage survival compared with
untreated controls was calculated.
Resected tumour studies
These experiments were carried out with animal care ethics
committee approval at McMaster University, Hamilton, Ontario,
Canada. Seven-week-old, male C3H/HeJ mice were used in these
studies. RIF-1 (murine radiation-induced fibrosarcoma) cells were
cultured in alpha-minimum essential medium (MEM) containing
10% FBS (Gibco, Canada). Cells were suspended in 1% Hanks'
buffered salt solution (HBSS, pH 7.4) (Gibco, Canada) at a
concentration of 1 x 107 cells per ml. Approximately 100 p1 of
these cells (1 x 106 cells) was injected into the right flank ofeach
mouse. The tumours were allowed to grow for 5 days (at which
time the tumours ranged from 6 to 8 mm in diameter). At day 5,
the mice were anaesthetized with a Ketamine-Rompom (70 mg
kg-':10 mg kg-') combination (0.02 ml g-'). An incision was
made 5 mm from the tumour edge and approximately 90% of
each tumour was removed and 150 mg of molten (50°C)
PCL-MEPEG-BMOV or PCL-MEPEG alone (control) was
extruded from a 500 pt syringe onto the entire surface of the
resected tumour site. The PCL solidified within 30 s and the area
was closed with 5-0 prolene sutures. The mice were examined on
days 4,5,6 and 7. On each day, tumours were measured (long and
short diameters) and images taken. When the tumours reached a
maximum diameter of 9 mm, the mice were sacrificed and the
tumour area was excised for future histological studies.
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Figure 1 Time course of BMOV release from PCL (150-mg slabs). (A) Drug
released (Rg) or (B) percentage of drug remaining in slab. Initial loading of
BMOV in PCL given by (0), 5%; (0), 10%; (A), 15%; (A), 20%; (E), 25%;
(A), 30% and (V), 35%
Tumour inhibition studies
These experiments were performed using 10-week-old DBA/2j
female mice with animal ethics committee approval at the
University ofToronto.
The MDAY-D2 haematopoetic cell line was obtained from Dr J
Dennis, Mount Sinai Hospital, Toronto, Canada. These cells were
plated or grown in suspension in Dulbecco's modified Eagle
medium (DMEM) containing 5% FBS (Gibco, Canada). Each
mouse was injected subcutaneously on the posterior lateral side
with 4 x 105 cells in 100 [tl of PBS. After 5 days' tumour growth,
150 mg ofthe PCL or PCL-BMOV molten paste was implanted in
an area adjacent to the tumour site of each mouse. After 15 days,
the mice were sacrificed, weighed and the tumours dissected and
weighed.
Statistical significance was determined using the Student's T-
test at P <0.05
RESULTS
In vitro drug-release experiments
The release of BMOV from the PCL matrix is shown in Figure 1.
Increasing the loading of BMOV from 5% to 35% in the PCL
matrix increased the rate of drug release over the 2-month
period (Figure IA). At 35% BMOV loading, the release rate
increased markedly. The release profiles for the 20% to 30%
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Figure 2 Time course of BMOV release from 150-mg slabs of PCL-MEPEG
(80:20, ww) expressed as (A) drug released (Rtg) or (B) percentage drug
remaining in slab. Initial loading of BMOV in PCL-MEPEG given by (0), 5%;
(0), 10%; (A), 15% and (A), 20%
BMOV loadings showed an initial more rapid phase of drug
release in the first 2 days followed by a controlled, almost zero-
order, release over the next 2 months.
The drug-release profiles are also expressed in terms of the
percentage of drug remaining in the pellet (Figure 1B). The
percentage of BMOV remaining in the PCL matrix was almost
identical at all time points for all the BMOV loadings up to (and
including) 30%, so that between 65% and 80% of the original
BMOV was still present in the matrix after 2 months. (Only the
data for 25%, 30% and 35% BMOV loadings are shown in Figure
lB for clarity.) The percentage of drug remaining in the matrix
decreased more rapidly at a loading of 35% BMOV, so that
approximately 50% of the original BMOV was present in the
matrix after 1 month. In order to verify the cumulative drug-
release data, samples ofthe PCL-BMOV matrix were assayed for
remaining drug content at the endofeachdrug-release experiment.
The percentage ofdrug remaining at 70 days as determined by this
residual assay was as follows: 67% ± 10% (5% BMOV), 56% +
10% (10% BMOV), 80% ± 20% (15% BMOV), 84% + 20% (20%
BMOV), 85% + 12% (25% BMOV), 77% + 14% (30% BMOV)
and 57% + 15% (35% BMOV).
Figure 2 shows the effect of adding 20% MEPEG to the PCL
matrix on the drug-release profiles for various loading concentra-
tions of BMOV. The addition of MEPEG to the matrix increases
the release rate of BMOV dramatically compared with the release
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Figure 3 Scanning electron micrographs of (A) BMOV crystals, (B) surface
morphology of the PCL slab containing 20% BMOV at the start of the drug-
release experiment and (C) surface morphology of the PCL slab containing
20% BMOV at the end of the drug-release experiment (72 days in PBS)
of BMOV from the PCL alone (Figure 1.). More than 50% of the
BMOV was released from the polymer matrix within 7 days at all
BMOV loading concentrations. Residual analysis of the
PCL-BMOV-MEPEG pellets gave the following values for the
percentage ofBMOV remaining at 7 days in the pellets: 24% ±9%
(5% BMOV), 25% ± 8% (10% BMOV), 22% ± 4% (15%
BMOV), 27% ± 7% (20% BMOV).
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Figure 4 Effect of increasing concentration of BMOV on cell survival using
(A) 1-h exposure of cells to BMOV or (B) continuous exposure to BMOV.
Cells described by (0), HT-29 colon cells; (0), MCF-7 breast cells; (A),
Skmesl non-small-cell lung cancer cells and (A), normal bone marrow cells
Scanning electron micrographs of PCL-BMOV matrices
Figure 3A shows the morphology of the BMOV crystals under
high magnification. Figure 3B and C shows the morphology ofthe
surface of the polymer-drug matrices both before and after the 2-
month drug-release study in aqueous buffer. The PCL-BMOV
matrices for 15%, 20% and 30% BMOV loadings were typically
smooth on their extermal surfaces before the release study and a
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Table 1 Effect of BMOV-loaded paste on the weights of MDAY-D2 tumours
grown in mice.
Tumour weights (g)
Control 25% BMOV 30% BMOV 35% BMOV
Experiment 1 1.68 1.05 - -
1.01 0.48 - -
0.96 0.20 - -
0.91 0.14 - -
1.23 0.80 - -
Mean 1.16 0.53 - -
s.d. 0.32 0.39 - -
Experiment 2 1.15 - 0.02 0.36
1.12 - 0.17 0.50
1.04 - 0.13 0.15
2.05 - 1.40 0.69
1.02 - 0.37 0.16
2.25 - 0.20 0.00
Mean 1.57 - 0.38 0.31
s.d. 0.53 - 0.51 0.25
Experiment 3 1.03 0.49 0.25 0.45
0.79 0.37 0.27 0.31
0.66 0.27 0.19 0.22
1.25 0.32 0.43 0.34
0.51 0.29 0.31 0.24
Mean 0.84 0.34 0.35 0.31
s.d. 0.30 0.09 0.16 0.09
PCL paste (150 mg) containing either 25%, 30% or 35% BMOV was injected
subcutaneously into mice bearing MDAY-D2 tumours. Tumourweights were
determined after 10 days' treatment. Table 1 shows the results from three
separate experiments using 25% BMOV (Experiment 1) and 30% or 35%
BMOV (Experiment 2). Experiment 3 uses 25%, 30% and 35% BMOV (i.e. a
repeat experiment at all concentrations). Control data describes mice treated
with PCL containing no BMOV.
representative s.e.m. is shown in Figure 3B. Following incubation
in the aqueous buffer for 2 months, the external surfaces were
rough and pitted as shown in Figure 3C.
Bactec assay
At the 1-h exposure, the BMOV had no effect against any of the
tumour cell lines or the normal human marrow at any of the
concentrations tested, as shown in Figure 4A. Under continuous
exposure (Figure 4B), the HT-29 cells were sensitive to BMOV at
25 I.M (6% survival) and 50 F.M (0% survival), the MCF-7 breast
cells were sensitive at 10 FLM (41% survival),25 FiM (21% survival)
and 50 F.M (10% survival) and the SKMES1 NSC lung cells were
sensitive at the 25 I.m (2% survival) and 50 FLM concentrations
(12% survival). (Sensitivity defined as < 50% survival compared
with untreated controls.) Against the normal human bone marrow
cells, the 1-h exposure BMOV also had very little effect, even at a
concentration of50 FLM. Using a continuous exposure, the effect of
BMOV on the marrow cells was still not very pronounced, with
sensitivity (49% survival) observed at the 50 l.M concentration
only. Thus, the BMOV compound is only mildly myelosuppres-
sive at the concentrations and exposures tested.
Tumour inhibition studies
Table 1 shows the data for tumour weights from control mice
(PCL-no BMOV) and mice treated with 25%, 30% and 35%
BMOV-loaded PCL. There was a 54% inhibition oftumourgrowth
for 25% BMOV-loaded PCL (significant at P < 0.05). The 30%
and 35% BMOV loadings produced 76% and 80% inhibition of
tumour growth, respectively, and one of the six mice in the 35%
BMOV group showed complete eradication of the tumour. In a
third experiment, all three loadings of BMOV in PCL (25%, 30%
and 35%) were effective atinhibiting tumour growth by 59%,66%
and 64% respectively. In all these experiments, there was no visual
evidence of stress in the mice and no evidence ofweight loss.
Tumour resection studies
The RIF-1 tumour grew rapidly in mice. Four days after resection
of the tumour cells, a clearly defined tumour mound could be
observed below the skin of control mice. In order to monitor the
daily progression of tumour growth, the diameters of the mounds
were measured through the skin using calipers, and the size of the
tumour was expressed as a weight calculated using the equation:
tumour weight (g) = length (cm) x (width2)
2
The values of calculated tumour weights are given in Table 2.
When the diameters exceeded 8 mm, the mice were sacrificed in
accordance with animal care ethics committee regulations to
Table 2 Effect of BMOV-loaded PCL-MePEG paste on the weights of RIF-1 tumours grown in mice
Tumour weights (g)
Animal Treatment Day 4 Day 5 Day 6
1 Control 0.162 0.226
2 Control 0.131 0.146 0.114
3 Control 0.133 0.173 0.233
4 Control 0.000 0.024 0.027
5 Control 0.122 0.148 0.161
6 Control 0.173 0.078 0.164
7-12 5% BMOV 0.000 0.000 0.000
RIF-1 tumours were grown in mice for 5 days at which time 90% of the tumour was surgically removed and the resection site was treated with
150 mg of PCL-MePEG (80:20 ww) paste containing either no BMOV (control) or 5% BMOV. Tumour regrowth was determined on days 4, 5
and 6 following this treatment.
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prevent undue suffering to the animals. The 5% BMOV-PCL paste
inhibited tumourregrowth in all six mice by day 4. By day 6, none
of the BMOV-treated mice showed any signs of tumour regrowth,
whereas all the control mice had large tumours. This result was
confirmed when the animals were sacrificed and no tumours were
present in the BMOV-treated mice. At the end of the experiment
(before sacrifice), it was noted that the BMOV-treated mice had
signs of necrosis in normal tissue and abnormal wound healing
whereby the skin was discoloured with a large scab formation.
DISCUSSION
The cytotoxic effect of prolonged exposure of tumour cells to
vanadium compounds has been described previously (Cruz et al,
1995). In this study, the antineoplastic effect of BMOV has been
shown in vitro against three human cancer cells lines under condi-
tions that ensure continuous exposure to the drug. In these in vitro
studies, continuous exposure of human bone marrow cells to
BMOV was also shown to have only a mild myelosuppressive
effect at concentrations of BMOV that were cytotoxic to all three
tumour cell lines. These in vitro results confirm the potential of
BMOV as an antineoplastic agent. However, in vivo, this potential
may depend on the continuous exposure of the tumour cells to
BMOV. The requirement for continuous (or prolonged) exposure
to vanadium has been reported previously in vivo (Cruz et al,
1985), whereby the tumour inhibition effects of vanadium
compounds depended on repeated dosing.
Preliminary in vitro drug-release experiments showed that for
PCL pastes loaded with both vanadyl sulphate and sodium ortho-
vanadate, all the encapsulated drug was released within a few days
(data not shown). BMOV was found to be released very slowly
from the PCL matrix with almost ideal release characteristics for
the maintenance of sustained concentrations of vanadium. These
characteristics included only a small burst effect ofdrug release in
the first few days followed by almost zero-order release kinetics at
most drug loadings (Figure 1). BMOV is less water soluble than
vanadyl sulphate or sodium orthovanadate, and the hydrophobicity
of the molecule probably increases the affinity of the BMOV
molecules for the hydrophobic PCL matrix and decreases the rate
ofdrug release into an aqueous incubation medium.
In vivo experiments showed that asingle subcutaneous adminis-
tration ofPCL-BMOV paste inhibited MDAY-D2 tumourgrowth.
These findings are consistent with the findings by Cruz et al
(1995) demonstrating that daily administration of500[ig ofortho-
vanadate for 10 days inhibited MDAY-D2 tumour growth in mice
by over 85%. Interestingly, the in vitro drug-release profiles
showed that paste containing 25% and 30% BMOV released
approximately 500 [ig of BMOV per day, which is a similar daily
dosage to that used previously (Cruz et al, 1995). However, 35%
BMOV-loaded PCL paste, which was the most effective in
reducing tumour growth, released approximately twice this
amount of drug in vitro. These data suggest that the sustained
release of small quantities of vanadium compounds will be an
equally or more effective antineoplastic regimen compared with a
daily vanadate regimen.
Although PCL-BMOV paste was equally as effective as daily
subcutaneous injections in inhibiting tumour growth, the mice
showed no signs oftoxicity, such as changes in animal behaviour
or weight loss. These findings are in contrast to the toxicity
observed with intraperitoneal administration of vanadate in which
mice were sluggish and withdrawn (under stress) immediately
following injection and this was followed by weight loss. This
evidence oftoxicity would indicate thatthe intraperitoneal route of
administration of this drug would not be feasible in humans.
Although toxicity induced by intraperitoneal injections of vana-
date can be alleviated considerably by administering vanadate
subcutaneously, this toxicity can be completely prevented by
sustained release of vanadate with PCL-BMOV paste. Increased
stress and weightloss,commonly observed with daily injections of
high doses of vanadate, are most probably related to toxicity
induced by the high vanadate levels in the plasma immediately
after administration. Following intraperitoneal injections, the
plasma levels of vanadate increase to very high levels almost
immediately followed by a rapid clearance into the urine, as has
been described previously (Harris et al, 1984; Merritt et al, 1992).
Subcutaneous administration is likely to lead to high plasma
concentrations within the first few hours of treatment followed by
a rapid clearance. Using PCL-BMOV paste to provide sustained
release of vanadate for long periods should reduce large fluctua-
tions in plasma vanadate concentrations and decrease the likeli-
hood of vanadate-induced toxicity. These data are consistent with
our hypothesis that a slow sustained release of BMOV is equally
or more effective in reducing tumour growth and prevents vana-
date-induced toxicity.
It is interesting to compare the toxicity reported in this study of
the antineoplastic effects of BMOV in mice with studies into the
glucose-lowering effects of BMOV in rats in which similar dose
ranges were used (25 mg kg' and 10-20 mg kg' respectively)
(Yuen et al, 1995). Following rapid bolus i.v. injections ofvanadyl
sulphate or BMOV at 10 mg kg-' rats were lethargic and slightly
cyanotic and had diarrhoea for 2-4 h after administration of the
drugs. These symptoms were reported to be less severe for BMOV
compared with vanadyl sulphate. In the same study, the plasma
concentration ofBMOV in rats was found to be 48 [tg ml-' imme-
diately after the rapid i.v. injection, falling to 8 ptg ml-' by 5 min
and 0.8 [tg ml-' at 24 h, indicating the rapid clearance of BMOV
from plasma. The rapid i.v. injections of BMOV were found to be
ineffective in lowering plasma glucose levels; however, slow i.v.
infusion over 30 min was effective. These results in rats were
attributed to the rapid clearance of BMOV from plasma, empha-
sizing the need to maintain a minimal effective BMOV concentra-
tion in plasma for pharmacological activity (Yuen et al, 1995). In
an earlier study, Yuen et al (1993 b) showed that the maintenance
ofplasma BMOV levels at 0.8 tg ml-' for 6 months was an effec-
tive treatment for diabetes in rats with no deaths or signs of toxi-
city over that period.
Although the pharmacokinetic profile of BMOV in mice is
unknown, it is likely that BMOV is cleared rapidly from plasma.
Therefore, the signs of toxicity described for i.p. injections of
BMOV at a dose of 25 mg kg' in mice probably result from high
plasmaconcentrations ofthe drug following injection, which may be
reduced by subcutaneous injections and further reduced with the
PCL-BMOV paste injection. The rapid clearance of BMOV from
plasma (Yuen at al, 1995) and the need for a sustained dose of
BMOV for the treatment of tumours indicate that the PCL-BMOV
paste offers an effective dosage form for the use ofthis antineoplastic
agent, while simultaneously minimizing toxicity to the animals.
The addition of 20% MEPEG to PCL has been shown previ-
ously to improve the thermal flow properties of the paste by
reducing the viscosity of the matrix and the temperature at which
the polymer solidifies (Winternitz et al, 1996). These properties
are important in applying the paste to a tumour resection site as
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better coverage ofthe site is obtained under these conditions. The
addition of MEPEG to the BMOV-PCL paste matrix has been
shown to enhance the release rates ofBMOV in vitro (Figure 2) at
all BMOV-loading concentrations (5-20%) relative to the release
rates from BMOV-PCL (no MEPEG) (Figure 1). The 5% BMOV-
loaded PCL-MEPEG paste was shown to release between 500 and
1000 [ig of BMOV per day (which was similar to the release rate
from 35% BMOV-loaded PCL). Since the 35% BMOV-loaded
PCL paste had produced no stress in mice over the course ofthe 2-
week tumour inhibition study, treatment of resected tumour sites
with 150 mg of 5% BMOV-loaded PCL-MEPEG paste was
considered to be safe for the mice. In all the mice studied, this
treatment prevented tumourregrowth completely, while all control
mice had rapidly regrowing tumours (Table 2).
In these initial resection studies, the 5% BMOV-loaded paste
was shown to be 100% effective against an extremely vigorous
RIF tumour. However, there was evidence of toxic side-effects,
such as tissue necrosis and abnormal wound healing. It is possible
that much lower BMOV drug concentrations at the resection site
are able to inhibit tumour growth. Therefore, future studies are
directed towards reducing both the MEPEG concentration and the
released dose of BMOV for the optimal treatment of resection
tumour regrowth.
The data presented in this study describe the effective antineo-
plastic activity of a slow-release formulation of the organic vana-
dium complex BMOV in vivo (using two tumourmodels). A single
PCL-BMOV paste injection was shown to be an effective dosage
form of this drug for the purpose of inhibiting tumour growth or
regrowth from a resected tumour site. Importantly, this route of
administration has no associated toxicity problems encountered
with daily intraperitoneal injections (or, to a lesserdegree, subcuta-
neous injections) ofBMOV. Furtherexperiments are in progress to
determine the long-term efficacy and toxicity of BMOV in mice
after PCL-BMOV paste injections together with pharmacokinetic
studies aimed at determining the minimum sustained plasma
concentration ofBMOV necessary for tumour inhibition.
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